Table 3.
Patient characteristics in FT rate matched cohort
| mSOR (n = 35) | mCON (n = 35) | p | |
|---|---|---|---|
| Age (years old), median [IQR]a | 65.5 [61.7, 71.5] | 68.1 [59.3, 75.3] | 0.47 |
| Gender (male), n (%) | 29 (82.9%) | 21 (60.0%) | 0.034 |
| FT rateb, median [IQR] | 1.90 [1.49, 2.30] | 1.91 [1.48, 2.30] | 0.99 |
| RFAsc, mean ± SD | 4.74 ± 2.72 | 2.83 ± 1.60 | <0.001 |
| TACEsd/TAIse, mean ± SD | 3.37 ± 2.99 | 2.34 ± 2.88 | 0.14 |
| RFAs/TACEs/TAIs, mean ± SD | 8.80 ± 4.37 | 5.97 ± 3.71 | 0.004 |
| HCV+, n (%) | 24 (68.6%) | 28 (80.0%) | 0.27 |
| Child-Pugh class (B/C), n (%) | 10 (28.6%) | 14 (40.0%) | 0.31 |
| Albumin (g/dL), median [IQR] | 3.8 [3.4, 4.2] | 3.6 [3.2, 3.9] | 0.016 |
| Total-bilirubin (mg/dL), median [IQR]) | 1.0 [0.7, 1.3] | 1.0 [0.7, 1.5] | 0.57 |
| ALT (IU/mL), median [IQR] | 54 [36, 79] | 54 [34, 96] | 0.80 |
| PT activity (%), median [IQR] | 74.3 [65.7, 80.6] | 71.2 [64.3, 76.9] | 0.54 |
| Platelet count (×103/μL), median [IQR] | 9.7 [7.3, 14.1] | 8.3 [6.5, 10.6] | 0.094 |
| AFPf (ng/mL), median [IQR] | 17.0 [8.0, 78.5] | 73.4 [18.4, 256.0] | 0.030 |
| DCPg (mAU/mL), median [IQR] | 33 [21, 292] | 38 [22, 132] | 0.98 |
| Tumor count, mean ± SD | 1.68 ± 0.90 | 1.86 ± 1.12 | 0.48 |
| Tumor diameter (mm), mean ± SD | 25.9 ± 9.4 | 26.9 ± 11.7 | 0.67 |
aInterquartile range
bFrequency of RFAs/TACEs/TAIs treatment per year
cNumber of radiofrequency ablation
dNumber of transcatheter arterial chemoembolization
eNumber of transcatheter arterial infusion
fAlpha-fetoprotein
gDes-γ-carboxy prothrombin